Alzheimer’s disease drugs in trial phase II by mechanism of action 2023
As of January 1, 2023, 85 percent of Alzheimer’s disease drugs in clinical trial phase II of development worldwide were disease-modifying therapies, of which 49 percent were small molecule therapies. This statistic illustrates Alzheimer’s disease drugs in phase II of development worldwide as of 2023, by mechanism of action.